

10/522086
DT01 Rec'd PCT/PTC 21 JAN 2005

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) An antibody against protein C or activated protein C (aPC), comprising the activity of potentiating an activity of activated protein C *in vivo*.
2. (Original) An antibody against protein C or activated protein C, comprising the activity of suppressing the inactivation of activated protein C *in vivo*.
3. (Original) An antibody against protein C or activated protein C, comprising the activity of suppressing: (a) the inactivation of activated protein C caused by blood or (b) the inactivation of activated protein C caused by a physiological inhibitor of activated protein C, or both (a) and (b).
4. (Original) The antibody of claim 3, wherein the physiological inhibitor of activated protein C is a serine protease inhibitor (SERPIN).
5. (Original) The antibody of claim 4, wherein the serine protease inhibitor (SERPIN) is a protein C inhibitor or α 1-antitrypsin.

6. (Currently Amended) The antibody of ~~any one of claims 1 to 3~~ claim 1, comprising a complementarity-determining region comprising any one of the amino acid sequences of (a) to (f), or a complementarity-determining region functionally equivalent thereto:

- (a) the amino acid sequences of SEQ ID NOs: 9, 10, and 11;
- (b) the amino acid sequences of SEQ ID NOs: 21, 22, and 23;
- (c) the amino acid sequences of SEQ ID NOs: 31, 32, and 33;
- (d) the amino acid sequences of SEQ ID NOs: 24, 25, and 34;
- (e) the amino acid sequences of SEQ ID NOs: 15, 16, and 17; and
- (f) the amino acid sequences of SEQ ID NOs: 27, 28, and 29.

7. (Currently Amended) The antibody of ~~any one of claims 1 to 3~~ claim 1, wherein the antibody is selected from the group consisting of a human antibody, humanized antibody, chimeric antibody, antibody fragment, single-chain antibody, and diabody.

8. (Currently Amended) A composition comprising the antibody of ~~any one of claims 1 to 3~~ claim 1, and a pharmaceutically acceptable carrier.

9. (Original) The composition of claim 8, further comprising protein C and/or activated protein C.

10. (Currently Amended) The composition of claim 8[[or 9]], wherein the composition is a pharmaceutical composition that can be used to prevent or treat a disease which is developed and/or advanced upon a decrease or loss of an activity of activated protein C.

11. (Original) The composition of claim 10, wherein the disease is developed upon the enhancement of the blood coagulation reaction and/or inflammatory reaction.

12. (Original) The composition of claim 11, wherein the disease developed upon the

enhancement of the blood coagulation reaction and/or inflammatory reaction is selected from the group consisting of sepsis, disseminated intravascular coagulation syndrome, arterial thrombosis, and venous thrombosis.

13. (Currently Amended) A method for producing protein C or activated protein C whose inactivation has been suppressed, comprising the step of contacting the antibody of ~~any one of claims 1 to 3~~ claim 1 with protein C or activated protein C.

14. (Currently Amended) A method for preventing or treating a disease developed and/or advanced upon a decrease or loss of an activity of activated protein C, comprising the step of administering: (a) protein C and/or activated protein C, and (b) the antibody of ~~any one of claims 1 to 3~~ claim 1.

15. (Currently Amended) A kit for preventing or treating a disease developed and/or advanced upon a decrease or loss of an activity of activated protein C, wherein the kit comprises (a) at least one selected from the group consisting of protein C, activated protein C, and an antibody of ~~any one of claims 1 to 3~~ claim 1, and (b) a recording medium comprising a description about a combined use of the antibody with protein C and/or activated protein C in a therapeutically effective amount, or a link to the description.